greeksoup/ stock research
Stock research / United States / RDY / Year to 31 March 2017

Dr. Reddy’s Laboratories Limited (RDY) annual results, year to 31 March 2017: revenue INR 140,809 million, from the 20-F

Dr. Reddy’s Laboratories Limited files a 20-F with the SEC once a year, in Indian rupees. In the year to 31 March 2017 it reported revenue of INR 140,809 million ($2.1 billion at the year's average rate), down 9.0% on the year before. Its profit attributable to shareholders was INR 12,039 million, down 39.8%, and diluted earnings per share INR 72.09.

Revenue
INR 140,809 million
-9.0% on the year
FY2016FY2017
Operating margin
9.6%
19.1% a year earlier
FY2016FY2017
Net income
INR 12,039 million
-39.8% on the year
FY2016FY2017
Diluted EPS
INR 72.09
-38.4% on the year
FY2016FY2017

this yearthe year beforeIn Indian rupees as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2016Mar 2017
Revenue154,708140,809
Cost of sales62,42762,453
Gross profit92,28178,356
Research and development17,83419,551
Selling, general and administrative45,70246,372
Operating profit29,61913,498
Finance costs4,959781
Profit before tax27,14014,653
Income tax7,1272,614
Profit for the year20,01312,039
Profit attributable to shareholders20,01312,039
Filing20-F20-F
INR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2016Mar 2017
Diluted EPS116.9872.09
Basic EPS117.3472.24
Filing20-F20-F

INR per ordinary share, as filed.

Cash flow

Year toMar 2016Mar 2017
Cash from operations41,24721,513
Purchase of property, plant and equipment12,01712,278
Free cash flow29,2309,235
Cash from investing-20,423-18,471
Cash from financing-17,001-3,692
Depreciation and amortisation10,25011,277
Buybacks0.015,694
Dividends paid4,1063,390
Filing20-F20-F

INR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2016Mar 2017
Funded by
Equity attributable to shareholders128,336124,044
Borrowings, as filedn/a49,098
Other liabilitiesn/a46,679
Total equity and liabilitiesn/a219,821
Owned
Property, plant and equipmentn/a57,160
Goodwilln/a3,752
Other intangible assets20,79644,925
Cash and cash equivalentsn/a3,866
Trade and other receivablesn/a38,065
Inventoriesn/a28,529
Other assetsn/a43,524
Total assetsn/a219,821
Filing20-F20-F

INR million, at each fiscal year end.

Ratios on the filed lines

Year toMar 2016Mar 2017
Gross margin59.6%55.6%
Operating margin19.1%9.6%
Net margin12.9%8.5%
Free cash flow margin18.9%6.6%
Return on year-end equity15.6%9.7%
Effective tax rate26.3%17.8%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2017, filed 3 June 2019: the filing. The figures are in Indian rupees as filed.